Q&A on Venture Investing During a Public Market Slump
This article was originally published in Start Up
Executive Summary
Question: How does the distressed state of the public market for biotech stocks impact venture capital funding of private biotech companies?Answer: Public market conditions should have no material effect on the total amount of venture capital funding available for biotech companies, although it may well have an impact on the investment profile of venture capital fund commitments,
You may also be interested in...
Horses for Courses: Why VCs Stick with Private, Not Public Investing
With public markets up but private equity markets still in the doldrums, why don't VCs shift their strategies to favor purchasing public biotechs? They have--a bit. But public investing doesn't exploit a VC's competitive advantages or justify the relatively high management fees they charge.
Corporate Venture Capital's Complex Agenda
Several forces--rapid technological obsolescence, the impact of information technology on health care, merger integrations, and the need for double digit revenue growth--have caused increasing numbers of large pharmaceutical and medical device companies to create new corporate venture capital groups. But compared to traditional VC firms, whose only goal is to make money for limited partners, corporate VCs have a heavy agenda. They must choose portfolio companies while balancing often-competing goals of strategic benefit and financial return.
Why Clinical Trials Fail Unexpectedly
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.